Abigail K. Suwala

Mannheim, BW, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 66 publications

Author Correction: IDH1-mutant vaccine in newly diagnosed astrocytoma: final analysis of the multicenter, single-arm, open-label, first-in-human phase 1 NOA16 trial.

Author Correction: IDH1-mutant vaccine in newly diagnosed astrocytoma: final analysis of the multicenter, single-arm, open-label, first-in-human phase 1 NOA16 trial.

Journal: Nature cancer
Published: August 03, 2026

Methodological considerations in the assessment of hemizygous CDKN2A/B deletions in meningioma and IDH-mutant glioma.

Methodological considerations in the assessment of hemizygous CDKN2A/B deletions in meningioma and IDH-mutant glioma.

Journal: Neuro-oncology
Published: July 06, 2026

Hemizygous deletion of CDKN2A/B in IDH-mutated glioma: Prognostic impact when adjusting for clinical factors.

Hemizygous deletion of CDKN2A/B in IDH-mutated glioma: Prognostic impact when adjusting for clinical factors.

Journal: Neuro-oncology advances
Published: February 26, 2026

Primary mismatch repair deficient glioma, IDH-wildtype and H3-wildtype: A giant cell tumor with potential for long-term survival occurring at all ages.

Primary mismatch repair deficient glioma, IDH-wildtype and H3-wildtype: A giant cell tumor with potential for long-term survival occurring at all ages.

Journal: Neuro-oncology
Published: December 15, 2025

Primary Mismatch Repair Deficient Glioma (PMMRDG), IDH-wildtype and H3-wildtype: A Giant Cell Tumor with Potential for Long-Term Survival Occurring at all Ages.

Primary Mismatch Repair Deficient Glioma (PMMRDG), IDH-wildtype and H3-wildtype: A Giant Cell Tumor with Potential for Long-Term Survival Occurring at all Ages.

Journal: Neuro-oncology
Published: December 15, 2025

IDH1-mutant vaccine in newly diagnosed astrocytoma: final analysis of the multicenter, single-arm, open-label, first-in-human phase 1 NOA16 trial.

IDH1-mutant vaccine in newly diagnosed astrocytoma: final analysis of the multicenter, single-arm, open-label, first-in-human phase 1 NOA16 trial.

Journal: Nature cancer
Published: October 30, 2025

Spatial Transcriptomics Characterisation of Radionecrotic Changes in Glioblastoma Patients.

Spatial Transcriptomics Characterisation of Radionecrotic Changes in Glioblastoma Patients.

Journal: Neuro-oncology
Published: September 05, 2025

Spatial transcriptomics characterisation of radionecrotic changes in glioblastoma patients.

Spatial transcriptomics characterisation of radionecrotic changes in glioblastoma patients.

Journal: Neuro-oncology
Published: September 05, 2025

Early distant progression in adult Histone-3 K27-altered diffuse midline gliomas.

Early distant progression in adult Histone-3 K27-altered diffuse midline gliomas.

Journal: Journal of neuro-oncology
Published: September 05, 2025

Loss of global DNA hypermethylation is prognostic in IDH-mutant and 1p/19q-codeleted oligodendrogliomas.

Loss of global DNA hypermethylation is prognostic in IDH-mutant and 1p/19q-codeleted oligodendrogliomas.

Journal: Acta neuropathologica
Published: August 26, 2025

The prognostic impact of CDKN2A/B hemizygous deletions in meningioma.

The prognostic impact of CDKN2A/B hemizygous deletions in meningioma.

Journal: Neuro-oncology
Published: August 13, 2025

Expansion of the spectrum of tumors diagnosed as myxopapillary ependymomas.

Expansion of the spectrum of tumors diagnosed as myxopapillary ependymomas.

Journal: Acta neuropathologica
Published: August 06, 2025
Showing 1-12 of 66

Last Updated: 09/26/2026